InnaVirVax announces presentation of the results of its Phase I/IIa clinical study at CROI 2013 in Atlanta
During the 20th Conference on Retroviruses and Opportunistic
Infections in Atlanta, InnaVirVax is presenting interim findings
from its Phase I/IIa study which confirm the safety of VAC-3S and
demonstrate its immunogenicity.
Atlanta, Evry (France), 5 March 2013 – InnaVirVax, a
biopharmaceutical company specialized in research and development
on therapeutic and diagnostic solutions for diseases linked to
immune dysregulation, is today announcing the presentation of
interim findings from its Phase I/IIa trial on VAC-3S, an
immunotherapeutic vaccine to treat HIV-related infections, during
the 20th CROI (Conference on Retroviruses and Opportunistic
Infections) which is taking place in Atlanta from 3 to 6 March
2013.
According to the most recent data collected during this
double-bind, placebo-controlled clinical study in 25 patients
living with HIV, under antiretroviral therapy and controlling their
viral load with a CD4 T- lymphocyte count higher than 200/mm3,
VAC-3S has demonstrated:
- safety at the three doses tested,
- an immune response among patients treated at the two highest
doses.?
?
?After all the study patients had received their three injections,
neither serious adverse effects nor viral rebounds were observed.
The VAC-3S injections were well tolerated. Data described in the
poster indicate that VAC-3S can induce the anticipated immune
response.?This double-blind study is being carried out in two
reference centres in Paris Public Academic Hospitals (AP-HP): at
Hôpital de la Pitié-Salpêtrière and
Hôpital Cochin.?
?Dr Shahin Gharakhanian, Chief Medical Officer (CMO)* of
InnaVirVax, based at the Cambridge Innovation Center in Cambridge,
Massachusetts, USA, stated: "We are presenting the preliminary
findings of our Phase I/IIa study to the scientific and medical
community who can now analyse and discuss these results These
interim data are encouraging as they describe initial findings with
respect to immunogenicity. This all supports our plans for VAC-3S,
which include filing an application for a phase II clinical study
in order to pursue the clinical development of VAC-3S as an
immunoprotective agent in combination with antiretrovirals. This
future phase II study will notably evaluate different optimised
immunisation regimens for VAC-3S".
Joël Crouzet, CEO of InnaVirVax, concluded: "We are very proud
to have been selected by the CROI, one of the most prestigious
events in the HIV world. These clinical data obtained with VAC-3S
candidate immunotherapy are very promising and have been achieved
less than five years after InnaVirVax was set up. Presenting them
in the context of a prestigious congress confirms the validity of
our strategy to use VAC-3S in order to protect a patient's immune
system."
About InnaVirVax:
Based in the Genopole® incubator hub in Evry, InnaVirVax is a
biopharmaceutical company specialized in research and development
on therapeutic and diagnostic solutions for diseases linked to
immune dysregulation. Through its understanding of immune
dysregulations, the company has developed a portfolio of innovative
products for use in HIV and oncology. The most advanced project
concerns an immunotherapy (VAC-3S) for the treatment of HIV
infections and has reached Phase I/IIa. Set up in 2008, the company
has since received support from the French Ministry for Higher
Education and Research, OSEO, the National Research Agency (ANR),
the Ile-de-France Centre for Innovation, and investors which
include CapDecisif, G1J Ile-de-France, Pradeyrol
Développement, Fa Dièse and the Fonds Régional
de Co-Investissement Ile-de-France. For more information, go to:
www.innavirvax.fr.
Contacts:
InnaVirVax
Joel CROUZET – CEO Tel.: +33 1 80 85 60 83
jc@innavirvax.fr
Milestones – Press Relations
Bruno ARABIAN
Tel.: +33 1 75 44 87 40 / +33 6 87 88 47 26
barabian@milestones.fr
Posted: March 2013
